Table II.

Clonal persistence following adoptive transfer

	PBMC Sample Daya	Lymphocyte Number Per mm3 (days 5–15)	Persistence Total (%)b	Lymphocyte Number Per mm3 (days 23–63)	Persistence Total (%)b
Responder
6(2)c	9, 55	2,085	49	1,646	24
9	9, 29	21,436	96	7,086	96
10	7, 23	12,150	94	3,410	84
16	7, 61	389	36	973	14
17(2)c	8, 28	555	43	1,328	10
19	5, 33	1,956	57	2,740	12
21	6, 27	1,407	45	1,079	15
25	7, 31	168	56	455	8
26	8, 34	711	44	483	2
28	9, 63	576	74	1,382	7
30(2)c	5, 26	111	61	283	11
31	7, 26	739	36	643	4
34	9, 37	82	62	639	51
Mean		3,258	58	1,704	26
SE		1,756	5	515	9
Nonresponder
7	15, 37	NDd	9	1,893	<1
11	8, 35	810	4	760	<1
12	8, 35	791	5	864	9
13	8, 29	1,073	36	1,027	<1
14	8, 29	532	<1	1,792	<1
15	7, 34	760	60	871	5
18	13, 29	287	2	385	<1
20	8, 25	548	18	592	2
22	8, 34	305	41	307	1
24	7, 29	2,282	87	535	41
27	7, 24	2,496	47	200	1
29	8, 32	164	25	186	<1
Mean		913	28	784	5
SE		225	8	163	3
		p2 = 0.663e	p2 = 0.008	p2 = 0.115	p2 = 0.001

^aThe days given are relative to the date of TIL infusion.

^bThe values indicate the sum of the percentages of individual clonotypes detected in PBMC samples that were also present in the administered TIL.

^cPatients 6, 17, and 30 had received a single prior ablation followed by an adoptive transfer of autologous TIL.

^dA PBL count was not carried out for patient no. 7 at this time point.

^eThe lymphocyte counts and the percentage of persistent clonotypes present in responders and nonresponders were compared using the Wilcoxon rank sum test.